Patent · US Active

T cell receptors and immune therapy using the same

US10550182B2 · kind B2 · utility

2Cited by

1References

8Claims

0Family size

Assignee

Immatics Biotechnologies GmbH · DE

Inventors

Leonie ALTEN · Lörrach, DE
Dominik MAURER · Lingen (Ems), DE
Steffen Walter · Dußlingen, DE
Sebastian BUNK · Wien, AT

Key dates

Filing date	Aug 15, 2017
Grant date	Feb 4, 2020
Priority date	—
Expiry date	Aug 15, 2037

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07K2319/00
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The present invention pertains to antigen recognizing constructs against COL6A3 antigens. The invention in particular provides novel T cell receptor (TCR) based molecules which are selective and specific for the tumor expressed antigen COL6A3. The TCR of the invention, and COL6A3 antigen binding fragments derived therefrom, are of use for the diagnosis, treatment and prevention of COL6A3 expressing cancerous diseases. Further provided are nucleic acids encoding the antigen recognizing constructs of the invention, vectors comprising these nucleic acids, recombinant cells expressing the antigen recognizing constructs and pharmaceutical compositions comprising the compounds of the invention.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.